Drug intelligence / Profile preview

KN5502

Development stage
Preclinical
Lead developer
Rui Therapeutics
Modality
CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration
Intravenous
01

Overview

KN5502 is a chimeric antigen receptor (CAR)-engineered natural killer (NK) cell therapy being developed by Rui Therapeutics (Shenzhen Enrui Kainuo Biotechnology Co., Ltd.). The therapy is designed to leverage the innate cytotoxic potential of NK cells, enhanced by the specificity of a chimeric antigen receptor to target and eliminate specific cells. As of early 2024, KN5502 is in the early preclinical research and development stage, with its specific molecular target and therapeutic indication currently undisclosed by the developer.

Other names
KN5502-Rui Therapeutics-CAR-NK cell therapyKN-5502-Rui Therapeutics-CAR-NK cell therapyKN 5502-Rui Therapeutics-CAR-NK cell therapy

Beyond the preview

Go deeper on KN5502.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on KN5502.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call